August 27, 2022 - New Frontiers in Cancer Research Clinical Symposium


Memorial Sloan Kettering Cancer Center (MSK) hosted its first virtual clinical symposium in India, where we enjoyed robust presentations, question and answer sessions, and conversations with oncologists from across India. Topics included the inherent challenges and opportunities in studying cancers globally, new digital tools and pathways for managing cancer care, translational research, germline testing, and more.

Register to Watch the Event

Symposium Agenda and Presenters


Title Presenter

Databases – Lessons From 3 Decades

Dr. Sir Murray Brennan, Senior Vice President of International Programs; Benno C. Schmidt Chair in Clinical Oncology
Going Forward – Reaping the Investment  Dr. Mrinal Gounder, Medical Oncologist; Physician Ambassador to India and Asia
Challenges and Opportunities for Studying Cancers Globally  Dr. Jatin Shah, Elliot W. Strong Chair in Head and Neck Oncology
Ayushman Bharat Digital Mission Shri RS Sharma, CEO, National Health Authority (India)
Digital Pathology Evolution at MSK – The Springboard to AI Dr. Meera Hameed, Chief, Surgical Pathology Service
Translational Research at MSK – The Road Ahead Dr. Ross Levine, Laurence Joseph Dineen Chair in Leukemia Research; Chief, Molecular Cancer Medicine Service, HOPP; Deputy Physician-In-Chief, Translational Research, Memorial Hospital
Environment and Cancer – Obesity, Inflammation, and Cancer  Dr. Neil Iyengar, Medical Oncologist, and Dr. Atul Batra, Associate Professor of Medical Oncology (All India Institute of Medical Sciences, New Delhi)
The Role of the Intestinal Microbiome in Cancer Immunotherapy Dr. Marcel van den Brink, Head, Division of Hematologic Malignancies; Alan N. Houghton Chair
Germline Testing to Inform Inherited Cancer Diagnosis, Management, and Prevention Dr. Kenneth Offit, Chief, Clinical Genetics Service; Robert and Kate Niehaus Chair in Inherited Cancer Genomics
Overview of Phase I (Early Drug Development) Program at MSK and  Potential for Collaborative Clinical Trials Dr. Alexander Drilon, Chief, Early Drug Development Service
Childhood Cancers – Progress and Promise  Dr. Andrew Kung, Chair, Department of Pediatrics
Conclusion Dr. Sir Murray Brennan